For Immediate Release
Chicago, IL – November 19, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Alphabet (GOOGL - Free Report) , Amazon (AMZN - Free Report) , Johnson & Johnson (JNJ - Free Report) , Boeing (BA - Free Report) and PetroChina (PTR - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for Alphabet, Amazon and Johnson & Johnson
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet, Amazon and Johnson & Johnson. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Alphabet’s shares have outperformed the Zacks Internet Services industry year to date (+27.6% vs. 9.5%). The Zacks analyst believes that the company’s strong focus on innovation of AI techniques and the home automation space should aid business growth in the long term. Also, its strong focus on bolstering presence in the cloud market is encouraging.
Alphabet reported weak third-quarter earnings due to heavy investment in cloud computing and hardware businesses. However, Google’s robust mobile search is a positive. Notably, it has agreed to acquire Fitbit for roughly $2.1 billion.
This deal will likely help the company to accelerate innovation in the wearables category. However, the company’s growing litigation issues and competition might hurt profitability.
Shares of Amazon have lost 6.4% in the past six months against S&P 500’s rise of 9.6%. The Zacks analyst believes that the company benefited from solid Prime momentum owing to robust grocery services and strong content portfolio.
Moreover, Prime Free One Day service helped Amazon in gaining traction across customers. Further, strengthening AWS services and its growing adoption rate contributed well to the third-quarter results. Improving Alexa skills and features remains a major positive. Expanding smart home products offerings are tailwinds.
However, rising transportation cost related to its free one-day shipping service remains an overhang and is likely to escalate further. Amazon also expects foreign exchange headwinds to continue impacting the top line.
Johnson & Johnson’s shares have gained 2% over the past three months against the Zacks Large Cap Pharmaceuticals industry's rise of 6.3%. The Zacks analyst believes that J&J is witnessing significant generic/biosimilar headwinds in the Pharma unit in 2019.
However, the unit is performing above-market levels supported by contribution from new drugs like Tremfya and successful label expansion of cancer drugs like Imbruvica and Darzalex and immunology drug, Stelara. J&J is also making rapid progress with its pipeline/line extensions. It has already gained FDA approval for two new drugs in 2019, Balversa and Spravato.
Share buybacks and restructuring initiatives should provide bottom-line support. However, headwinds like biosimilar/generic competition and pricing pressure remain. Moreover, J&J faces numerous lawsuits, which allege personal injuries to patients caused by the use of its products.
Other noteworthy reports we are featuring today include Boeing and PetroChina.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.5% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.